D76.1
Hemophagocytic lymphohistiocytosis
Clinical Classification Guidelines
Inclusion Terms
- Familial hemophagocytic reticulosis
- Histiocytoses of mononuclear phagocytes
Medical Intelligence & Overview
Hemophagocytic lymphohistiocytosis (HLH) is a rare, severe condition characterized by an overactive immune system. In HLH, the body's immune cells become overly activated, leading to widespread inflammation and damage to organs. This condition can affect individuals of all ages but is more common in infants and young children. Understanding HLH is crucial because, if left untreated, it can be life-threatening. The disorder can occur in a familial form, known as familial hemophagocytic reticulosis, or develop as a result of other underlying health issues.
Causes & Symptoms
Clinical Causes: Genetic mutations that impair the immune system's ability to regulate immune responses Secondary triggers such as infections (e.g., viral, bacterial, fungal), which can provoke the condition in susceptible individuals Underlying immune disorders or malignancies Certain medications that interfere with immune function
Key Symptoms: High fever that doesn't resolve Persistent fatigue and weakness Swollen lymph nodes in the neck, groin, or other areas Enlarged spleen or liver causing abdominal discomfort Unexplained bleeding or easy bruising Skin rashes or discoloration Shortness of breath Neurological symptoms including irritability, seizures, or decreased consciousness Laboratory findings such as low blood cell counts (anemia, leukopenia, thrombocytopenia)
Diagnostic & Treatment
Diagnosis Path: Diagnosis of HLH involves a combination of clinical evaluation and laboratory tests. Key diagnostic criteria include persistent fever, organ enlargement, abnormal blood cell counts, elevated levels of certain blood proteins like ferritin, and evidence of hemophagocytosis in bone marrow, spleen, or lymph nodes. Specialized blood tests, genetic studies, and imaging might be performed to confirm the diagnosis and identify any underlying causes.
Treatment Protocols: Treating HLH typically requires a prompt and aggressive approach to control the overactive immune response. Common treatments include immunosuppressive therapies such as corticosteroids, chemotherapy drugs like etoposide, and targeted biological agents that help modulate immune activity. In cases of familial HLH, hematopoietic stem cell transplantation may be considered to restore normal immune function. Supportive care to manage symptoms and prevent complications is also essential.
Clinical Advice & FAQs
Billing Guidance
Is D76.1 a billable ICD-10 code?
Yes, D76.1 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report D76.1?
Clinical documentation must specify the nature of Hemophagocytic lymphohistiocytosis and any associated comorbidities for accurate reporting.
Cite this Clinical Reference